Improved discrimination of prostate cancer and benign prostatic hyperplasia by means of the quotient of free and total PSA

International Urology and Nephrology

Volumn 31, Issue 3, 1999, Pages 351-359

  Weckermann, D ^a   Maassen, C ^a   Wawroschek, F ^a   Harzmann, R ^a  

^a KLINIKUM AUGSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; PROTEIN DETERMINATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; ROC CURVE;

EID: 0033451987     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007178203861     Document Type: Article

References (22)

1. Bangma, C. H., Kranse, R., Blijenberg, B. G., Schröder, F. H.: The value of screening tests in the detection of prostate cancer. Part 1 : Results of a retrospective evaluation of 1726 men. Urology. 46, 773 (1995).
2. Bangma, C. H., Kranse, R., Blijenberg, B. G., Schröder, F. H.: The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J. Urol., 157, 544 (1997).
3. Bangma, C. H., Rietbergen, J. B. W., Kranse, R., Blijenberg, B. G., Petterson, K., Schröder, F. H.: The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J. Urol., 157, 2191 (1997).
4. Catalona, W. J., Smith, D. S., Wolfert, R. L., Wang, T. J., Rittenhouse, H. G., Ratliff, T. L., Nadler, R. B.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA, 274, 1214 (1995).
5. Catalona, W. J., Ornstein, D. K., Humphrey, P. A., Smith, D. S.: Factors affecting the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. J. Urol., 157 (Suppl.), 433 (1997).
6. Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Patel, A., Flanigan, R. C., Richie, J. P., de Kernion, J. B., Walsh, P. C., Scardino, P. T., Lange, P. H., Herschman, J. D., Subong, E. N. P., Petteway, J. C., Parson, R. E., Loveland, K. G., Gasior, G. H., Southwick. P. C.: A multicenter clinical trial evaluation of free PSA in the differentiation of prostate cancer from benign disease. J. Urol., 157 (Suppl.), 434 (1997).
7. Christensson, A., Björk, T., Nilsson, O., Dahlén, U., Matikainen, M, T., Cockett, A. T. K., Abrahamsson, P. A., Lilja, H.: Serum prostate specific antigen complexed to αl-antichymotrypsin as an indicator of prostate cancer. J. Urol., 150, 100 (1993).
8. Froschermaier, S. E., Pilarsky, C. P., Wirth, M. P.: Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma. Urology, 47, 525 (1996).
9. Jung. K., Meyer, A., Lein, M., Rudolph, B., Schnorr, D., Loening, S. A.: Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. J. Urol., 159, 1595 (1998).
10. Lein, M., Stephan, C., Jung, K., Koenig, F., Schnorr, D., Loening, S. A.: Das Verhältnis freies PSA/Gesamt-PSA - eine Kenngröße zur Differenzierung zwischen Patienten mit Prostatakarzinom und benigner Prostatahyperplasie: Welcher Diskriminationspunkt sollte gewählt werden? (Ratio of free-PSA / total-PSA: an indicator for differentiation between patients with prostate cancer and benign prostatic hyperplasia). Akt. Urol., 28, 323 (1997).
11. Masters. J. G., Keegan, P. E., Hildreth, A. J., Greene, D. R. J.: Free/total serum prostate-specific antigen ratio: how helpful is it in detecting prostate cancer? Br. J. Urol., 81, 419 (1998).
12. Murphy, G. P., Barren, R. J., Erickson, S. J., Bowes, V. A., Wolfert, R. L., Bartsch, G., Klocker, H., Pointner, J., Reissigl, A., McLeod, D. G., Douglas, T., Morgan, T., Kenny, G. M., Ragde, H., Boynton, A. L., Holmes, E. H.: Evaluation and comparison of two new prostate carcinoma markers. Cancer, 78, 809 (1996).
13. Ornstein, D. K., Smith. D. S., Humphrey, P. A., Catalona, W. J.: The effect of prostate volume, age, tolal prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. J. Urol., 159, 1234 (1998).
14. Partin, A. W., Oesterling, J. E.: The clinical usefulness of percent free-PSA. Urology, 48 (6A), 1 (1996).
15. Partin, A. W., Catalona, W. J., Southwick, P. C., Subong, E. N. P., Gasior, G. H., Chan D. W.: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume and age. Urology, 48 (6A), 55 (1996).
16. Prestigiacomo, A. F., Lilja, H., Pettersson, K., Wolfert, R. L., Stamey, T. A.: A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: The best case scenario. J. Urol., 156, 350 (1996).
17. Semjonow, A., Oberpenning, F., Brandt, B., Zechel, C., Brandau, W., Hertle, L.: Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology, 48 (6A), 10 (1996).
18. Stamey, T. A., Chen, Z., Prestigiacomo, A.: Serum prostate-specific antigen binding αl-antichymotrypsin: Influence of cancer volume, location and therapeutic selection of resistant clones. J Ural., 152, 1510 (1994).
19. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K., Alfthan, O.: A complex between prostate-specific antigen and αl-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51, 222 (1991).
20. Van Cangh, P. J., de Nayer, P., de Vischer, L., Sauvage, P., Tombal, B., Lorge, F., Wese, F. X., Opsomer, R.: Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/ml total PSA. Urology, 48 (6A), 67 (1996).
21. Vashi, A. R., Wojno, K. J., Vessella, R. L., Lange, P. H., Wright, G. L. Jr., Schellhammer, P. F., Oesterling, J. E.: Percent free PSA correlates directly with patient age. J. Urol., 157 (Suppl.), 432 (1997).
22. Woodrum, D., French, C., Shamel, L. B.: Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology, 48 (6A), 33 (1996).